

Yingli Ma, Ph.D.

Shanghai, China

SUMMARY

10+ years' pharma-biotech drug discovery experience with rapidly increased responsibilities. Currently lead 40+ scientists with diverse expertise in structural biology, biophysics, modeling and AI, antibody discovery, *in vitro* and *in vivo* pharmacology, GPCR biology and medicinal chemistry. Responsible for Amgen Shanghai Research site discovery research activities with delivery of small molecule and biologics hits and leads to support Cardiometabolic Diseases and Neuroscience. Responsible for technology evaluation and scouting, capability expansion through strategic external collaboration, site operational excellence and general business development.

PROFESSIONAL EXPERIENCES

Amgen Asia R&D Center, June 2014 - present

Site Council Lead, Oct 2018 - present

- Overall leadership responsibility for site operation excellence, connectivity to Amgen overall R&D and JAPAC regional activities, and site initiatives
- Represent Amgen in China to stakeholders including those in government, scientific community and industry

Director, Therapeutic Discovery, July 2018 - present

- Overall leadership responsibility for Shanghai site therapeutic discovery (Pharmacology, Medicinal Chemistry and DEL, antibody discovery and optimization, molecular modeling and early discovery AI, structural biology and biophysics) with delivery of early small molecule and biologics hits for Cardiometabolic Diseases and Neuroscience
- Responsible for external collaboration, business development and site operation.
- Technology evaluation and scouting, capability expansion through strategic academic and CRO collaboration

Project Leader, Antibody for Obesity, Feb 2018 - present

- Formulate project strategy, including immunization strategies for challenging therapeutic targets including GPCR
- Immunogen design, generation and QC
- Generation, screening and characterization of large panel of therapeutic single-domain antibodies through differentiated technology platforms (NGS, high content screening, function-based screening, characterization and optimization)
- Move therapeutic biologics molecules through pre-clinical models and towards testing in human

Principal Scientist, Lead, Structural Biology and Protein Expression, June 2014-July 2018

- From 0 to 1: build the team and fully establish GPCR crystallography capability
- Solve and deliver novel GPCR structures and support GPCR SBDD
- Establish cryoEM collaboration with Tsinghua Univ.
- Establish expression platform to support structural biology and discovery research
- Work with an interdisciplinary team of biologists, chemists, and protein scientists including leading academic labs and CROs to establish structural biology capability for GPCR targets and drive scientific innovation

- Hands-on work including construct design, purification, characterization, LCP crystallization screening, data collection and processing, and structure determination of GPCR targets
- Technology scouting and capability expansion through strategic academic collaboration

GlaxoSmithKline, Shanghai, R&D China, Apr. 2009 - May 2014

Principal Scientist, Structural Chemistry group leader, PTS (Platform Technology Science)

May 2011 - May 2014

Senior Scientist, Informatics and Structural Biology, Apr. 2009 - Apr. 2011

- Formulate strategies of structural and biophysical support across all DPUs in China and execute to meet deliverable timelines
- Support multiple preclinical drug discovery programs across a variety of target class (kinase, PPI, channel, membrane receptor, nuclear receptor etc) for target validation, protein characterization and structural biology studies, in the fields of neuroscience, regenerative medicine and mitochondria biology. Contributed directly to milestone achievements including C2T, HTS and CS.
- Lead FBDD (fragment-based drug discovery) effort in support of chemical tractability evaluation of targets and delivery of alternative chemical starting point for lead optimization
- Lead 3 internal FTEs and 1 external FTE, coordinate CRO and global resources for cloning, protein expression & purification, crystallography, and biophysics (NMR, SPR, ITC, Tm etc)
- Evaluate and establish academic collaborations for capability and tech. expansion

POSTDOCTORAL RESEARCH EXPERIENCE

Postdoctoral Associate, Rockefeller University, New York, Aug 2005-Apr 2009

Gunter Blobel lab (Nobel Laureate, 1999)

REWARDS AND RECOGNITION

Best Speaker Award	2017	3 rd DIA China Drug Discovery Innovation Conference
Nominated for HBA "Rising Star"	2017	Amgen Inc.
Scientific Innovation Award (team lead)	2016	Amgen Inc., Discovery Research
Annual Star (team lead)	2016	Amgen Biopharm R&D (Shanghai)
Annual Star	2015	Amgen Biopharm R&D (Shanghai)
Quarterly Luminary Star	2015 Q2	Amgen Biopharm R&D (Shanghai)
Short list, Zhangjiang Talent (final 30)	2015	Zhangjiang Talent
Impact Award, Silver	2012	GSK, Shanghai
Impact Award, Silver	2011	GSK, Shanghai
Exceptional Science Award	2010	GSK, Shanghai

EDUCATION

Ph.D., Biochemistry and Molecular Biophysics, 2005, Univ of Pennsylvania, Philadelphia, PA

Thesis Advisor: Professor Gregory D. Van Duyne

Thesis Title: "Structure of the Gemin6/7 heterodimer from the SMN complex reveals similarity with Sm proteins"

B.S., Clinical Medicine, 1998

China Medical University, Shenyang, China